Excelsior collects $95M on mission to accelerate discovery, production of small molecules
8.0
来源：
FiercePharma
发布时间：
2025-12-03 09:39
摘要：
Excelsior Sciences has secured $95 million in funding to advance its AI-driven platform for small molecule drug discovery. The New York-based company aims to automate chemical synthesis using its innovative smart bloccs technology, which could transform drug development processes. With a focus on reshoring manufacturing, Excelsior's approach aligns with the growing trend of integrating AI in biopharma, positioning it as a key player in the industry.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.0
technical_barrier_competition
0.5
关键证据
Excelsior is gaining ground on its quest to hasten the discovery and production of small molecules.
The funding haul includes a $70 million series A round that was co-led by Deerfield, Khosla Ventures and Sofinnova Partners.
Excelsior asserts that it is developing a new form of chemistry that machines can do and AI can use to enable closed-loop drug discovery.
真实性检查
否
AI评分总结
Excelsior Sciences has secured $95 million in funding to advance its AI-driven platform for small molecule drug discovery. The New York-based company aims to automate chemical synthesis using its innovative smart bloccs technology, which could transform drug development processes. With a focus on reshoring manufacturing, Excelsior's approach aligns with the growing trend of integrating AI in biopharma, positioning it as a key player in the industry.